NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Down 10.2%
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY)’s stock price was down 10.2% on Tuesday . The stock traded as low as $0.75 and last traded at $0.82, approximately 2,392,064 shares were traded during trading. An increase of 91% from the average daily volume of 1,252,650 shares. The stock had previously closed at $0.91.
Separately, Zacks Investment Research cut NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th.
The stock’s fifty day simple moving average is $0.68.
About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.